Lymphoma Specialized Program of Research Excellence (SPORE)

尽管淋巴细胞恶性肿瘤有进展，但大多数仍然无法治愈，并导致患者死亡。爱荷华大学/梅奥诊所淋巴瘤孢子（UI/MC孢子）是一个非常成功的转化研究项目，它利用了爱荷华大学霍尔顿综合癌症中心和梅奥诊所综合癌症中心的转化淋巴瘤项目的综合优势-两个nci指定的综合癌症中心。在前一个供资期间，UI/MC的生产力很高。科学成就包括探索一种新型治疗剂的潜力的转化研究，免疫刺激CpG ODN，作为B细胞恶性肿瘤的潜在治疗方法，开发新的成像方法，可能影响我们对淋巴瘤生物学的理解，以及研究可能对淋巴瘤管理产生重大影响的生物标志物。作为UI/MC孢子的一部分，已经开展了五项早期治疗性临床试验，其中包括在爱荷华州和梅奥大学进行的四项研究。自2002年启动UI/MC孢子以来，96名受试者参加了治疗试验，17名受试者参加了新型成像试验。作为UI/MC淋巴瘤孢子分子流行病学资源的一部分，在爱荷华州和梅奥医院收集了1331名受试者的DNA和广泛的临床数据，这将越来越有价值，作为识别导致淋巴瘤发生和治疗反应的遗传因素的工具。

Despite progress in lymphoid malignancies, most are still incurable and lead to the death of the patient. The University of Iowa/Mayo Clinic Lymphoma SPORE (UI/MC SPORE) is a highly successful translational research program that takes advantage of the combined strengths of the translational lymphoma programs of the Holden Comprehensive Cancer Center at the University of Iowa and the Mayo Clinic Comprehensive Cancer Center - two NCI-designated comprehensive cancer centers. During the prior funding period, the UI/MC has been highly productive. Scientific accomplishments include translational studies exploring the potential of a novel therapeutic agent, immunostimulatory CpG ODN, as a potential treatment for B cell malignancies, development of novel approaches to imaging that could impact on our understanding of lymphoma biology, and investigation into biomarkers that could have a significant impact on management of lymphoma. Five early phase therapeutic clinical trials have been opened as part of the UI/MC SPORE, including four studies that have accrued subjects at both Iowa and Mayo. Since initiation of the UI/MC SPORE in 2002, 96 subjects have been enrolled on therapeutic trials and 17 on novel imaging trials. DNA and extensive clinical data have been collected on 1331 subjects at Iowa and Mayo as part of the UI/MC Lymphoma SPORE Molecular Epidemiologic Resource which will be increasingly valuable as a tool for identifying genetic factors that contribute to lymphomagenesis and response to therapy. This renewal application is designed to accelerate the progress of the UI/MC SPORE and consists of four research projects, four core resources, and the Career Development and Developmental Research Programs. Specific projects are as follows: 1) A novel approach to the immunotherapy of B cell malignancies 2) Signal transduction inhibitor therapy for lymphoma 3) Biology and Epidemiology of APRIL and BLyS in B-cell NHL 4) Regulatory T-cells in the tumor microenvironment of B-cell non-Hodgkin lymphoma Core resources include Administration, Biostatistics and Bioinformatics, Biospecimens, and Clinical Research that supports both clinical trials and the Molecular Epidemiology Resource of the UI/MC SPORE. All units within the UI/MC SPORE work to draw on the resources of both institutions to expedite the translation of discoveries into new and better approaches to the prevention and treatment of lymphoma.